RxDoctor Payments Data

Vivek Gill, MD

Internal Medicine · Phelan, CANPI 1992712616

Payments from drug & device makers

$4,199in general payments, 2019–2025

Across 116 payments — averaging $36.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$752
  • Johnson & Johnson$712
  • Bayer$521
  • Novo Nordisk$423
  • SK Life Science, Inc.$278
  • plus $418 from 6 others

What the payments were for

  • Food & beverage$4,189100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,199 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$29,671
Medicare patients
122
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin318$327,486
OzempicSemaglutide100$103,110
EliquisApixaban34$54,952
Breztri AerosphereBudesonide/Glycopyr/Formoterol53$47,724
RybelsusSemaglutide33$45,993
JanuviaSitagliptin Phosphate30$35,697
TradjentaLinagliptin26$35,499
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$34,782
TrulicityDulaglutide23$29,893
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog62$26,595
XareltoRivaroxaban32$22,944
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$22,655
FarxigaDapagliflozin Propanediol13$16,757
SteglatroErtugliflozin Pidolate19$12,385
Spiriva HandihalerTiotropium Bromide11$12,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$752$372,091363 claims
Novo NordiskOzempic, Rybelsus$423$149,104133 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$1,095$67,96777 claims
GSKTrelegy Ellipta, Anoro Ellipta$167$57,43663 claims
PfizerEliquis$69$54,95234 claims
Johnson & JohnsonXarelto, Invokana$712$30,12344 claims
Lilly USA, LLCTrulicity$69$29,89323 claims
Sanofi-aventis U.S. LLCLantus$69$4,61046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Phelan

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →